SYSevil Tuğrul Yavuz

Sevil Tuğrul Yavuz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sevil Tuğrul Yavuz has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of left ventricular end-systolic volume with peri-echocardiographic acute kidney injury proxy beyond ejection fraction: a retrospective linked echocardiographic cohort study

    by Hasan Burak Isleyen, Sevil Tugrul Yavuz, Sercan Bulut, Fatih Kizkapan, Cevahir Alioglu, Necla Zeynep Eren, Ali Arda Sozen, Mahsa Khanmohammadi

    Left ventricular ejection fraction (LVEF) remains the default echocardiographic summary of systolic performance, yet its ratio structure makes it sensitive to geometry and loading conditions. Left ventricular end-systolic volume (LVESV) may capture adverse remodeling more directly. The relation of LVESV to peri-echocardiographic renal dysfunction in hospitalized patients remains uncertain. This retrospective linked echocardiographic cohort study analyzed 1,022 complete biplane studies from 784 patients in the credentialed PhysioNet MIMIC-IV-ECHO-Ext-LVVOLUMES-A4C-ROI resource linked to MIMIC-IV v3.1 clinical tables. The primary endpoint was an acute kidney injury (AKI) proxy defined as maximum serum creatinine ≥ 2.0 mg/dL within a ± 24-hour peri-echocardiographic window. Hierarchical logistic regression with patient-level cluster-robust standard errors included age, sex, first-day SOFA score, and vasopressor exposure; 5 chained-equation imputations addressed missing SOFA. Temporal analysis compared echocardiography time with the first creatinine value meeting the endpoint threshold. AKI proxy was present in 80 of 1,022 studies (7.8%). Among these 80 studies, 73 (91.3%) reached the creatinine threshold before echocardiography and 7 (8.8%) after echocardiography. For AKI proxy, LVESV showed modestly higher discrimination than LVEF (AUC 0.572 vs. 0.548; ΔAUC 0.024; p = 0.253). In the fully adjusted hierarchical model, LVESV remained associated with AKI proxy (OR 1.40 per SD increase, 95% CI 1.10-1.78; p = 0.006), whereas LVEF did not (OR 0.83 per SD decrease, 95% CI 0.62-1.10; p = 0.188). Model 3 yielded the highest C-statistic (0.727) and the lowest AIC (517.0), but BIC was not improved and reclassification gains were modest. LVESV was associated with peri-echocardiographic AKI proxy after severity adjustment, but the temporal analysis indicates that the signal predominantly reflected concurrent renal illness rather than prospective prediction. Any incremental value beyond LVEF was modest and should be interpreted within the limits of a non-KDIGO creatinine-based proxy endpoint.

  • Open Access

    Troponin T, Left Ventricular Ejection Fraction, and Tricuspid Regurgitation Velocity for Biomarker- and Echocardiography-Based Risk Stratification in Critically Ill Patients with Heart Failure

    by Hasan Burak Isleyen, Sevil Tugrul Yavuz, Sercan Bulut, Fatih Kizkapan, Cevahir Alioglu, Ali Arda Sozen, Mahsa Khanmohammadi

    Troponin T is a molecular marker of cardiomyocyte injury, whereas left ventricular ejection fraction (LVEF) and tricuspid regurgitation velocity (TRV) reflect downstream ventricular and cardiopulmonary measures. This study evaluated whether synchronized troponin T and echocardiographic data can identify mortality risk in critically ill patients with heart failure, while separating statistical association from clinically meaningful incremental discrimination. Adult intensive care unit admissions with heart failure diagnoses were identified from MIMIC-IV and MIMIC-IV-ECHO. The primary endpoint was 28-day all-cause mortality; one-year mortality was secondary. Multivariable Cox models were adjusted for demographics, comorbidity, illness severity, organ support, and laboratory covariates. Restricted cubic splines, proportional hazards diagnostics, variance inflation factors, prespecified subgroup interaction tests, complete-case analyses, and multiple imputation sensitivity analyses were performed. The final cohort included 4362 patients, and 1072 patients (24.6%) died within 28 days. In the primary complete-case Cox model (n = 2087; 659 deaths), higher log-transformed troponin T was associated with higher 28-day mortality (hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.03–1.15; p = 0.003), and higher LVEF was associated with lower mortality (HR per percentage point, 0.99; 95% CI, 0.99–1.00; p = 0.004). After severity and organ-support covariates were entered, troponin T and LVEF produced statistically detectable but very small C-statistic gains. Measurable TRV was available in 1546 patients and was associated with mortality in that subset (HR, 1.28; 95% CI, 1.08–1.52; p = 0.005). Troponin T, LVEF, and TRV were associated with mortality in ICU heart failure. Their contribution was best interpreted as risk enrichment within a clinical severity framework rather than a stand-alone decision rule.


  • Open Access

    Development and Temporal Validation of the SAKARYA Model for Early Cardiorenal Risk Stratification in Critically Ill Adults with Acute Heart Failure: A Credentialed Database Analysis

    by Hasan Burak Isleyen, Sercan Bulut, Sevil Tugrul Yavuz, Esra Danışman

    Acute heart failure in the intensive care unit has a high early cardiorenal burden, whereas most existing risk tools were derived outside critical care. This retrospective cohort study used MIMIC-IV version 3.1. Adults with a first intensive care unit admission, a heart failure diagnosis, and enrichment by early intravenous loop diuretic treatment or BNP/NT-proBNP testing were included. Core predictors were measured within 6 hours of admission. The primary outcome was 28-day death or incident creatinine-defined acute kidney injury. Derivation used admissions from 2009-2018 and temporal validation used admissions from 2019-2023. Bootstrap internal validation, spline screening, strict sensitivity analyses, and strict comparator analyses against SOFA and BUN+SBP were performed. The broad clean core cohort included 7065 patients, with 5399 in derivation and 1666 in temporal validation. The primary outcome occurred in 2289 derivation patients and 810 validation patients. The 11-variable SAKARYA model included age, sex, heart rate, mean arterial pressure, respiratory rate, oxygen saturation, creatinine, blood urea nitrogen, sodium, bicarbonate, and hemoglobin. Area under the receiver operating characteristic curve for the primary outcome was 0.636 in derivation and 0.648 in temporal validation; Brier scores were 0.231 and 0.238. Validation calibration intercept and slope were 0.26 and 0.99. Bootstrap optimism-corrected area under the curve was 0.631. A strict sensitivity cohort included 737 derivation and 296 validation patients. In strict temporal validation, area under the curve was 0.630 for SAKARYA, 0.682 for SOFA, and 0.607 for BUN+SBP. The broad primary model showed modest discrimination with preserved temporal calibration. After tightening phenotype timing and separating creatinine windows, performance remained modest and did not exceed SOFA. External multicenter validation and phenotype refinement are needed before clinical use.

  • Percutaneous Mechanical Mobilization of a Thrombosed Mechanical Tricuspid Valve After Failed Thrombolysis

    by Sevil Tuğrul Yavuz, Duygu İnAn, Burcu Aggül, Kadir Kasım Şahin, Alev Kılıçgedik

    Mechanical prosthetic tricuspid valve thrombosis is a rare but potentially life‐threatening condition. Evidence guiding management is limited, particularly in patients who are poor surgical candidates or who fail thrombolytic therapy. We report an 83‐year‐old woman with a mechanical tricuspid valve who presented with progressive right‐sided heart failure due to obstructive valve thrombosis. After failure of anticoagulation and low‐dose thrombolytic therapy, a percutaneous catheter‐based approach was performed. Using a steerable sheath and electrophysiology catheter, mechanical mobilization of the stuck leaflet was achieved, followed by thrombus aspiration. Leaflet mobility was restored, and transvalvular gradients significantly improved without complications. In carefully selected patients with mechanical tricuspid valve thrombosis who are not candidates for surgery and fail thrombolytic therapy, percutaneous mechanical mobilization may represent a feasible and effective bailout strategy.

  • Vericiguat in Experimental Atrial Fibrillation: Distinguishing Remodeling from Rhythm Control

    by Hasan Burak İşLeyen, Emirhan Hancıoğlu, Sevil Tuğrul Yavuz

    The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.

  • Tricuspid Regurgitation Severity and 1-Year Mortality in Echocardiography-Selected Adult Intensive Care Unit Patients: A Medical Information Mart for Intensive Care-IV-Echocardiogram Cohort Study

    by Sevil Tuğrul Yavuz, Sercan Bulut, Gurur Nar Sağır, Hasan Burak İşLeyen

    Objective: To evaluate the association between tricuspid regurgitation (TR) severity measured near intensive care unit (ICU) admission and 365-day all-cause mortality in echocardiography-selected adult ICU patients. Methods: This secondary analysis linked Medical Information Mart for Intensive Care-IV (MIMIC-IV) version 3.1 with MIMIC-IV-echocardiogram. Adults with transthoracic echocardiography from 24 hours before to 72 hours after ICU admission and documented TR severity were included. None/trivial and mild TR were combined as the low-grade reference group; moderate and severe TR were compared with this group. Multiple Cox regression analyses evaluated 28-, 90-, and 365-day mortality. Sodium-adjusted and biomarker-availability analyses evaluated additional laboratory information. Results: The cohort included 16 991 patients: 12 417 (73.1%) had low-grade, 3467 (20.4%) moderate, and 1107 (6.5%) severe TR. Crude mortality increased across TR severity at 28 days (15.1%, 24.5%, and 32.7%), 90 days (20.3%, 32.5%, and 42.7%), and 365 days (27.2%, 42.9%, and 53.4%). Compared with low-grade TR, 365-day multiple-adjusted estimates were hazard ratio (HR) = 1.32, P < .001, 95% CI: 1.24-1.41 for moderate TR and HR = 1.67, P < .001, 95% CI: 1.52-1.83 for severe TR; 28- and 90-day estimates were directionally consistent, and sodium-adjusted estimates were similar. Conclusion: Moderate and severe TR on early echocardiography were associated with higher 1-year mortality in echocardiography-selected adult ICU patients. This observational association remained consistent after sodium adjustment but should not be interpreted as a treatment effect.

  • Open Access

    Kardiyolojide Kritik Kararlar: Klinik & Müdahale Stratejileri

    by Yusuf İnCi, Şevval Kılıç, İlYas Çetin, İhsan Demirtaş, Semih Kalkan, Mustafacan Kılıçoğlu, Uğur Ozan Demirhan, Berkay Mutlu, Sevil Tuğrul Yavuz, Mehmet Nail Bilen, et al.

  • The relation between breast artery calcification and subclinical left ventricular systolic dysfunction

    by Gurur Nar Sagir, Esra Donmez, Sevgi Ozcan, Sevil Tugrul Yavuz, İsHak Yilmaz, Nigar Erkoc, Ertugrul Okuyan, Irfan Sahin

    Cardiovascular diseases (CVD) are most common causes of mortality and morbidity. The presence of breast artery calcification (BAC) was shown to be associated with CVD. We aimed to determine the relationship between BAC and subclinical left ventricular systolic dysfunction (LVSD) by using strain echocardiography.Patients diagnosed with BAC between October 2023 and May 2024 were prospectively included. 100 age-matched patients without BAC were included as the control group. Patients were divided into two groups as BAC( +) and BAC(-) and further patients were grouped as LVSD( +) and LVSD(-) according to global longitudinal strain(GLS) measurements.A total of 94 patients with BAC( +) and 100 patients with BAC(-) were evaluated. When BAC(-) and BAC( +) groups were compared, GLS(-18.7 ± 2.6vs.-20.9 ± 1.7;p < 0.0001) was significantly lower in BAC( +) group and GLS was significantly decreased with increasing BAC grades (p < 0.0001). Significant deterioration in parameters indicating left ventricular diastolic function was observed in BAC ( +) group. BAC grade 3 (p = 0.002), increase in E/e' (p = 0.001), and NLr (p = 0.009) were identified as independent risk factors for LVSD. In the ROC analysis, a cut-off value of -17.3 for GLS was associated with 93.3% sensitivity of and 92.6%; specificity for predicting BAC grade 3.Presence of BAC is associated with subclinical LVSD and presence of BAC grade 3 is and independent predictor of LVSD. Detection BAC on screening mammograms may help to define patients under risk of heart failure development. Graphical Abstract

  • Open Access

    Investigation of the relationship between vascular events and copeptin levels in hospitalized COVID-19 patients

    by Aysegul Kirankaya, Levent Deniz, Sevil Tugrul, Sevgi Ozcan, Suat Hayri Kucuk, Zeynep Atam Tasdemir, Ertugrul Okuyan, Irfan Sahin

    Objectives: This study aimed to evaluate the effect of copeptin levels on the prediction of COVID-19-associated vascular events and mortality. Methods: This prospective observational study included 172 patients with COVID-19. In this study, the role of copeptin was assessed in hospitalized COVID-19 patients for in-hospital mortality, need for advanced ventilator support, intensive care unit (ICU) admission, and vascular events. We performed a regression analysis to identify independent risk factors for major ischemic events and in-hospital mortality in our study population. Results: During the hospitalization period of 172 patients, 24 had major ischemic events, 45 were admitted to the ICU, 43 needed advanced ventilator support, and 33 died. Regression analysis revealed that the copeptin level was an independent risk factor for both major ischemic events and in-hospital mortality. A cut-off value of 5.161 for copeptin level was associated with 54.2 % sensitivity and 85.1 % specificity (AUC: 0.727; 95 % CI: 0.654–0.792) in the prediction of major ischemic events, and a cut-off value of 3.304 for copeptin level was associated with 51.5 % sensitivity and 71.9 % specificity (AUC: 0.633; 95 % CI: 0.556–0.705) for predicting in-hospital mortality. Conclusions: Copeptin is a promising biomarker for predicting mortality and major ischemic events in hospitalized COVID-19 patients. Copeptin levels were significantly higher in ICU-admitted patients and those needing advanced ventilatory support. Copeptin may serve as an effective marker for identifying COVID-19 patients who can benefit from closer monitoring or early intensification of care.